ClinicalTrials.gg
Not yet recruitingNCT07636577Updated Jun 9, 2026

Nutrition Counseling, Diet Quality, and Advanced Glycation End Products in Gestational Diabetes

An interventional study of Structured Nutrition Counseling and Standard Care in Gestational Diabetes Mellitus and Pregnancy, sponsored by Istanbul Saglik Bilimleri University. Not yet recruiting. Open to female participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-09.

Sponsored by Istanbul Saglik Bilimleri University · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Female
01

Study summary

This study will evaluate the relationship between structured nutrition counseling, diet quality, and advanced glycation end products in pregnant women with gestational diabetes mellitus and women with normal glucose tolerance. Participants will be assigned to either a structured nutrition counseling group or a standard care group according to glucose tolerance status. The counseling program will include education and follow-up on healthy eating during pregnancy, gestational diabetes management, portion control, food choices, meal planning, and cooking methods. Diet quality, dietary habits, biochemical parameters, advanced glycation end products, gestational weight gain, and fetal outcomes will be assessed during follow-up.

02

Conditions studied

  • Gestational Diabetes Mellitus
  • Pregnancy

Keywords

  • Advanced Glycation End Products
  • Diet Quality
  • Nutrition Counseling
  • Dietary Habits
  • Highly Processed Food Consumption
03

In context

Diabetes, Gestational

877 studies on the registry are indexed under Diabetes, Gestational; 203 are open to participants now.

This study's planned enrollment of 48 is below the median of 110 across 564 interventional studies indexed under Diabetes, Gestational.

Browse Diabetes, Gestational studies →

Lead sponsor

Istanbul Saglik Bilimleri University is the lead sponsor of 60 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant women aged 18 to 35 years
  • Singleton and first pregnancy
  • Gestational age between 24 and 28 weeks at enrollment
  • Diagnosis of gestational diabetes mellitus or normal glucose tolerance
  • Not using insulin therapy
  • Stopped smoking at least 3 months before enrollment and not using alcohol
  • Willingness to participate in the study
  • Ability to provide written

Exclusion criteria

Exclusion Criteria:

  • Current use of insulin therapy
  • Active smoking
  • Alcohol use
  • Refusal or inability to provide written
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Active comparator
    NGT-Control

    Pregnant women with normal glucose tolerance receiving standard obstetric care and routine dietitian consultation.

    Other: Standard Care

  • Experimental
    NGT-Intervention

    Pregnant women with normal glucose tolerance receiving standard obstetric care plus structured nutrition counseling.

    Behavioral: Structured Nutrition Counseling · Other: Standard Care

  • Active comparator
    GDM-Control

    Pregnant women with gestational diabetes mellitus receiving standard gestational diabetes management and routine dietitian consultation.

    Other: Standard Care

  • Experimental
    GDM-Intervention

    Pregnant women with gestational diabetes mellitus receiving standard gestational diabetes management plus structured nutrition counseling.

    Behavioral: Structured Nutrition Counseling · Other: Standard Care

Interventions

  • BehavioralStructured Nutrition Counseling

    A dietitian-led structured nutrition counseling, education, and follow-up program provided in addition to standard care. The program includes education on pregnancy, gestational diabetes mellitus, adequate and balanced nutrition, appropriate gestational weight gain, portion control, low glycemic index food choices, reduction of highly processed foods, healthy cooking methods, carbohydrate intake, and meal planning. Follow-up will be conducted at least every two weeks by telephone, online, or face-to-face sessions. Dietary records and weight changes will be reviewed, and individualized feedback and motivational support will be provided.

  • OtherStandard Care

    Standard obstetric care or standard gestational diabetes management, when applicable, with routine dietitian consultation.

06

What researchers measure

Primary outcomes

  1. Diet Quality Score

    Diet quality will be assessed using the Diet Quality Index-International based on three-day food records. The score ranges from 0 to 100, with higher scores indicating better diet quality.

    Time frame: Baseline at 24-28 weeks of gestation and final assessment at 32-36 weeks of gestation

  2. Serum Advanced Glycation End Products Level

    Serum advanced glycation end products levels will be measured using serum samples obtained from residual blood collected during routine clinical tests. Levels will be evaluated in relation to glucose tolerance status, nutrition counseling, diet quality, and dietary behaviors.

    Time frame: Final assessment at approximately 32-36 weeks of gestation

Secondary outcomes

  1. Highly Processed Food Consumption Score

    Highly processed food consumption will be assessed using the short screening questionnaire of highly processed food consumption. Higher scores indicate higher consumption of highly processed foods.

    Time frame: Baseline at 24-28 weeks of gestation and after 8 weeks of follow-up at approximately 32-36 weeks of gestation

  2. Dietary Habits and Cooking Methods

    Dietary habits and cooking methods will be assessed using a structured questionnaire including meal frequency, skipped meals, snacking habits, food preferences, cooking methods, and types of oils used in food preparation.

    Time frame: Baseline at 24-28 weeks of gestation and after 8 weeks of follow-up at approximately 32-36 weeks of gestation

  3. Gestational Weight Gain

    Gestational weight gain will be evaluated using maternal body weight measurements recorded during pregnancy follow-up.

    Time frame: Baseline at 24-28 weeks of gestation and after 8 weeks of follow-up at approximately 32-36 weeks of gestation

  4. Birth Weight

    Infant birth weight will be recorded in grams after delivery from obstetric and neonatal records.

    Time frame: At delivery

  5. Gestational Age at Birth

    Gestational age at birth will be recorded in completed weeks after delivery from obstetric records.

    Time frame: At delivery

  6. Congenital Anomaly Status

    The presence or absence of congenital anomaly will be recorded after delivery from obstetric and neonatal records.

    Time frame: At delivery

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Sisay M, Edessa D, Ali T, Mekuria AN, Gebrie A. The relationship between advanced glycation end products and gestational diabetes: A systematic review and meta-analysis. PLoS One. 2020 Oct 21;15(10):e0240382. doi: 10.1371/journal.pone.0240382. eCollection 2020. PubMed 33085688 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared because the study includes sensitive health data from pregnant women. Data will be stored and analyzed in coded and anonymized form in accordance with the informed consent and ethics committee approval.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07636577
Lead sponsor
Istanbul Saglik Bilimleri University
Responsible party
Beyzanur Çamlıbel (Dietitian, PhD Candidate, Istanbul Saglik Bilimleri University) — Principal investigator
First posted
Jun 9, 2026
Start date
Aug 2026 (estimated)
Primary completion
May 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Jun 9, 2026

Study contacts

BEYZANUR ÇAMLIBEL, Dietitian / PhD Candidate
Contact
beyzanur.cmlbl@gmail.com
+90 541 656 78 19

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion